Limonene epoxide hydrolase mutants and their catalytic synthesis of chiral oxygen / nitrogen-heterocyclic compounds
Through the enzyme transformation of the LEH limonene epoxy hydrolase of Rhodococcus limonene, the problem of biosynthesis of chiral oxygen/nitrogen-heterocyclic compounds is solved, efficient and green catalytic synthesis is achieved, and a new method to replace traditional chemical methods is provided.
Patent Information
- Application Number
- CN202111491732.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-08
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-12-08
AI Technical Summary
In the prior art, biosynthesis methods of chiral oxygen/nitrogen-heterocyclic compounds are not common, especially the use of oxetane molecules as synthesizers to synthesize chiral oxygen/nitrogen-heterocyclic compounds has not been achieved, and traditional Chemical methods require precious metal catalysts and harsh reaction conditions.
Through directed evolutionary technology, the limonene epoxy hydrolase LEH of the genus Rhodococcus was transformed to obtain 4-(ethylene oxide-2-yl)-1-butanol and 3,3-disubstituted oxetine that can efficiently catalyze 4-(ethylene oxide-2-yl)-1-butanol and 3,3-disubstituted oxetine Mutants of alkyl substrates for biocatalytic synthesis of chiral oxygen/nitrogen-heterocyclic compounds.
The biocatalytic synthesis of chiral oxygen/nitrogen-heterocyclic compounds with high yield and high optical purity (high ee value) is achieved, avoiding precious metal catalysts and harsh reaction conditions, and providing a green and efficient synthesis method.
Smart Images

Figure CN116240194B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically relates to limonene epoxide hydrolase mutants, and more specifically to limonene epoxide hydrolase mutants obtained by enzyme modification of limonene epoxide hydrolase LEH from Rhodococcus erythropolis DCL14 using directed evolution technology and methods, and the use of these mutants as biocatalysts in chiral oxygen heterocyclic compounds. Background Art
[0002] Chiral oxygen / nitrogen-heterocyclic compounds are structural units of many biologically active molecules and are important pharmaceutical and fine chemical intermediates, such as the antibiotics monensin and clindamycin, the anticancer drug eribulin, the topical anti-infective drug mupirocin, and the antidepressant paroxetine.
[0003] At present, there are two methods for synthesizing chiral oxygen / nitrogen-heterocyclic compounds: chemical method and biosynthesis method. Chemical synthesis methods include: using cobalt complex as catalyst for ring-opening desymmetrization of oxetane molecules (Loy et al., J. Am. Chem. Soc., 2009, 131, 2786-2787), intramolecular dechlorination cyclization of chiral chloropolyols under microwave heating conditions (Kang et al., Org. Lett. 2010, 12, 1716-1719), and using bimetallic palladium / radium supported on graphite as catalyst for asymmetric hydrogenation reduction of epoxycarboxylic acids (Ullrich et al., ACS. Catal. 2018, 8, 785-789.) In recent years, research on asymmetric catalysis of small organic molecules has also made some progress (MacMillan et al., DW J Am. Chem. Soc. 2012, 134, 11400. List et al. al.Angew.Chem.Int.Ed.2019,58,12761) provides a new synthetic strategy for the asymmetric construction of nitrogen-containing heterocyclic compounds. However, traditional chemical methods use precious metals as chiral catalysts, require the addition of organic solvents, and have harsh reaction conditions.
[0004] The biosynthetic methods of chiral oxygen heterocyclic compounds include: the cytochrome P450 enzyme in the biosynthetic pathway of griseofulvin synthesizes the important benzofuranone skeleton through oxidative cyclization (Tang et al., ACS. Chem. Biol. 2013, 8, 2322-2330); in the biosynthesis of natural products, non-heme iron σ-ketoglutarate (σ-KG)-dependent oxygenase is another enzyme that synthesizes chiral five-membered oxygen-heterocyclic compounds (Tang et al., Chem. Rev. 2017, 117, 5226-5333.); however, the biosynthesis of chiral oxygen / nitrogen-heterocyclic compounds is not common at present, and the synthesis of chiral oxygen / nitrogen-heterocyclic compounds using oxetane molecules as synthons through biological methods has not yet been reported.
[0005] Limonene epoxide hydrolase LEH (EC 3.3.2.8) can catalyze the hydrolysis of epoxides and generate ortho-chiral diol products. Its optically pure products can be used as chiral building blocks for pharmaceutical intermediates and fine chemicals. The enzyme sequence is short, containing only about 150 amino acids, and does not rely on any cofactors. In addition, its structure-function relationship has a broad research foundation in the past few decades and can be used as a model enzyme for new reaction design. Therefore, it is of great application value to modify limonene epoxide hydrolase through directed evolution technology and methods to obtain green and efficient synthesis of chiral oxygen / nitrogen-heterocyclic compounds. Summary of the invention
[0006] The invention uses directed evolution technology and methods to modify the limonene epoxide hydrolase LEH from Rhodococcus erythropolis DCL14, obtains a mutant with high yield and high ee value for 4-(oxirane-2-yl)-1-butanol and 3,3-disubstituted oxetane substrates, and applies it to the biocatalytic synthesis of optically pure chiral oxygen / nitrogen-heterocyclic compounds, providing a new method for synthesizing chiral oxygen / nitrogen-heterocyclic compounds.
[0007] In a first aspect, the present invention protects a limonene epoxide hydrolase LEH mutant. The limonene epoxide hydrolase LEH mutant of the present invention is a protein obtained by mutating at least one of the amino acid residues located in the catalytic center pocket of the limonene epoxide hydrolase.
[0008] The amino acid residues of the catalytic center pocket of the limonene epoxide hydrolase LEH are the amino acid residues shown at positions 53, 55, 80, 83, 114 and 116 of the amino acid sequence of the limonene epoxide hydrolase LEH.
[0009] Among them, the 53rd, 55th and 132nd amino acid residues are all located in the active center of limonene epoxide hydrolase LEH, and are key amino acids for activating water molecules; the 80th, 83rd, 114th and 116th positions are active centers, controlling important chiral sites. These amino acid residues are all key sites that affect the enantioselectivity of limonene epoxide hydrolase LEH for substrates and the catalytic activity of the enzyme. By modifying these amino acid residues, the conversion rate of the substrate can be increased and different chiral oxygen heterocyclic compounds can be selectively obtained.
[0010] Furthermore, the limonene epoxide hydrolase LEH mutant is a protein obtained by mutating the amino acid residues shown at positions 53 and / or 55 and / or 80 and / or 83 and / or 114 and / or 116 of the amino acid sequence of limonene epoxide hydrolase LEH.
[0011] Furthermore, the limonene epoxide hydrolase LEH mutant includes at least one of the following mutations: mutating the 53rd position of the amino acid sequence of the limonene epoxide hydrolase LEH from tyrosine to leucine or isoleucine or valine or phenylalanine, mutating the 55th position of the amino acid sequence of the limonene epoxide hydrolase LEH from asparagine to proline or alanine, mutating the 80th position of the amino acid sequence of the limonene epoxide hydrolase LEH from isoleucine to phenylalanine, mutating the 114th position of the amino acid sequence of the limonene epoxide hydrolase LEH from valine, and mutating the 116th position of the amino acid sequence of the limonene epoxide hydrolase LEH from isoleucine to valine.
[0012] In a specific embodiment of the present invention, the limonene epoxide hydrolase LEH mutant is any one of the following (1)-(9):
[0013] (1) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to leucine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged;
[0014] (2) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to isoleucine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged;
[0015] (3) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to valine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged;
[0016] (4) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to isoleucine, and mutating the 55th amino acid from asparagine to alanine, while keeping the other amino acid sequences unchanged;
[0017] (5) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged;
[0018] (6) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, and mutating the 55th amino acid from asparagine to alanine, while keeping the other amino acid sequences unchanged;
[0019] (7) A protein obtained by mutating the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, the amino acid at position 55 from asparagine to alanine, the isoleucine at position 80 to phenylalanine, the leucine at position 114 to valine, and the isoleucine at position 116 to valine, while keeping the other amino acid sequences unchanged;
[0020] (8) A protein obtained by mutating the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, the amino acid at position 55 from asparagine to alanine, and the isoleucine at position 116 to valine, while keeping the other amino acid sequences unchanged;
[0021] (9) A protein obtained by mutating the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, the amino acid at position 55 from asparagine to alanine, the isoleucine at position 80 to phenylalanine, and the isoleucine at position 116 to valine, while keeping the other amino acid sequences unchanged;
[0022] (10) A fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of the protein shown in any one of (1) to (9).
[0023] In the above protein, the amino acid sequence of the limonene epoxide hydrolase LEH is shown in SEQ ID No. 1. The tag may be a tag shown in Table 1 below.
[0024] Table 1 Fusion expression protein tags
[0025]
[0026] The nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as mRNA or hnRNA.
[0027] A person skilled in the art can easily mutate the nucleotide sequence encoding the above-mentioned limonene epoxide hydrolase LEH mutant of the present invention by using known methods, such as directed evolution and point mutation. Those artificially modified nucleotides having 90% or higher identity with the nucleic acid molecule of the present invention, as long as they encode the limonene epoxide hydrolase LEH mutant and have the same function, are derived from the nucleic acid molecule of the present invention and are equivalent to the sequence of the present invention, and all belong to the protection scope of the present invention.
[0028] The term "identity" as used herein refers to sequence similarity to a natural nucleic acid sequence. "Identity" includes nucleotide sequences that have 90% or more, or 95% or more, or 98% or more, or 99% or more identity to the nucleotide sequence of the present invention encoding the protein consisting of the amino acid sequence shown in SEQ ID No.1. Identity can be evaluated by the naked eye or by computer software. Using computer software, the identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the identity between related sequences.
[0029] In the second aspect, the present invention protects any one of the following biological materials a1)-a4):
[0030] a1) an expression cassette containing a nucleic acid molecule encoding the above-mentioned limonene epoxide hydrolase LEH mutant;
[0031] a2) a recombinant vector containing a nucleic acid molecule encoding the above-mentioned limonene epoxide hydrolase LEH mutant;
[0032] a3) a recombinant microorganism containing a nucleic acid molecule encoding the above-mentioned limonene epoxide hydrolase LEH mutant;
[0033] a4) A transgenic cell line containing a nucleic acid molecule encoding the above-mentioned limonene epoxide hydrolase LEH mutant.
[0034] Furthermore, the expression cassette containing the nucleic acid molecule encoding the limonene epoxide hydrolase LEH mutant described in a1) refers to a DNA capable of expressing the limonene epoxide hydrolase LEH mutant in a host cell, and the DNA may include not only a promoter for initiating transcription of the limonene epoxide hydrolase LEH mutant encoding gene, but also a terminator for terminating transcription of the limonene epoxide hydrolase LEH mutant encoding gene. Furthermore, the expression cassette may also include an enhancer sequence.
[0035] a2) The recombinant vector containing the nucleic acid molecule encoding the above-mentioned limonene epoxide hydrolase LEH mutant can be a bacterial plasmid (such as an expression vector based on a T7 promoter expressed in bacteria, specifically pET-22b, etc.), a bacteriophage, a yeast plasmid (such as a YEp series vector, etc.) or a retroviral packaging plasmid carrying the gene encoding the limonene epoxide hydrolase LEH mutant.
[0036] a3) The recombinant microorganism containing the nucleic acid molecule encoding the limonene epoxide hydrolase LEH mutant described above can be yeast, bacteria, algae or fungi, such as Agrobacterium, etc., carrying the gene encoding the limonene epoxide hydrolase LEH mutant.
[0037] a4) The transgenic cell line containing the nucleic acid molecule encoding the above-mentioned limonene epoxide hydrolase LEH mutant does not include propagation material.
[0038] In a third aspect, the present invention protects new uses of the above-mentioned limonene epoxide hydrolase LEH mutant or the above-mentioned nucleic acid molecule or the above-mentioned biomaterial.
[0039] The present invention protects the use of the limonene epoxide hydrolase LEH mutant or the nucleic acid molecule or the biological material in any of the following A1)-A8):
[0040] A1) catalyzing 4-(oxiran-2-yl)-1-butanol to produce (S)-(tetrahydro-2H-pyran-2-yl)methanol;
[0041] A2) Synthesis or preparation of chiral (tetrahydro-2H-pyran-2-yl)methanol;
[0042] A3) Catalytic synthesis of (S)-(3-phenyltetrahydrofuran-3-yl)methanol from 2-(3-phenyloxetane-3-yl)ethanol
[0043] A4) Synthesis or preparation of chiral (3-substituted tetrahydrofuran-3-yl)methanol;
[0044] A5) Catalytic synthesis of (S)-(1-benzyl-3-phenyltetrahydropyridin-3-yl)methanol from N-benzyl-2-(3-phenyloxetane-3-yl)ethylamine
[0045] A6) Synthesis or preparation of (1-benzyl-3-aryltetrahydropyridin-3-yl)methanol;
[0046] A7) Catalytic synthesis of (1-benzyl-3-phenylpiperidin-3-yl)methanol from N-benzyl-2-(3-phenyloxetane-3-yl)propylamine
[0047] A8) Synthesis or preparation of (1-benzyl-3-substituted piperidin-3-yl)methanol;
[0048] The (tetrahydro-2H-pyran-2-yl) alcohol may be any one of the following: (tetrahydro-2H-pyran-2-yl) methanol, 1-(tetrahydro-2H-pyran-2-yl) ethane-1-ol, 2-(tetrahydro-2H-pyran-2-yl) propan-2-ol.
[0049] The (3-aryltetrahydrofuran-3-yl)methanol may be any of the following: (3-(4-methylphenyl)tetrahydrofuran-3-yl)methanol, (3-(3-methylphenyl)tetrahydrofuran-3-yl)methanol, (3-(3,5-dimethylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-ethylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-methoxyphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-methylthiophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-naphthylphenyl)tetrahydrofuran-3-yl)methanol (3-(4-fluorophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-chlorophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-bromophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-trifluoromethylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-benzyl)tetrahydrofuran-3-yl)methanol, (3-(4-ethyl)tetrahydrofuran-3-yl)methanol, (3-(4-methyl)tetrahydrofuran-3-yl)methanol, (3-phenyltetrahydro-2H-pyran-3-yl)methanol.
[0050] The (1-benzyl-3-aryltetrahydropyridine-3-yl)methanol can be any one of the following: (1-benzyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-allyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-propargyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-n-butyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-phenyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-phenyl-3-p-tolyltetrahydropyridine-3-yl)methanol, (1-phenyl-3-p-chlorophenyltetrahydropyridine-3-yl)methanol, (1-benzyl- (1-benzyl-3-(m-tolyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(3,5-xylyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-ethylphenyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-methoxyphenyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-methylthiophenyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-naphthyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(p-fluorophenyl)tetrahydropyridin-3-yl)methanol.
[0051] The (1-benzyl-3-substituted piperidin-3-yl)methanol may be any one of the following: (1-benzyl-3-phenylpiperidin-3-yl)methanol, (1-benzyl-3-benzylpiperidin-3-yl)methanol.
[0052] In the method, the host cell may be a prokaryotic cell or a lower eukaryotic cell. Further, the prokaryotic cell may be a bacterium; the lower eukaryotic cell may be a yeast cell. Further, the host cell may be Escherichia coli.
[0053] In one embodiment of the present invention, the host cell is E. coli BL21 (DE3). Accordingly, the induction culture is to add IPTG to the culture system to a final concentration of 0.05-1.0 mmol / L (such as 0.1 mmol / L), and to induce the culture at 20-30° C. (such as 20° C.) for 10-20 hours (such as 12 hours).
[0054] Further, the reaction composition of using the limonene epoxide hydrolase LEH mutant as a biological enzyme to catalyze the substrate to generate (S)-(tetrahydro-2H-pyran-2-yl)methanol or (S)-(3-phenyltetrahydrofuran-3-yl)methanol is as follows: whole cells of limonene epoxide hydrolase LEH or its mutant, lysozyme, DNase I (deoxyribonuclease), cosolvent acetonitrile, substrate, phosphate buffer, etc. The specific reaction system is: whole cells of limonene epoxide hydrolase LEH or its mutant 100g / L, lysozyme 1g / L, DNase I (deoxyribonuclease) 6U / mL, 5%-10% acetonitrile as cosolvent, and the balance is 50mM potassium phosphate buffer (pH7.4).
[0055] The concentration of the substrate in the reaction system is 1-50 mmol / L (such as 5 mmol / L); the concentration of the crude enzyme powder of the limonene epoxide hydrolase LEH mutant in the reaction system is 1-10 g / L (such as 10 g / L); the concentration of the whole cell of the limonene epoxide hydrolase LEH mutant in the above application is 50-500 g / L (such as 100 g / L); the concentration of the limonene epoxide hydrolase in the reaction system is 0.1-2 g / L (such as 0.5 g / L), and the volume percentage of the acetonitrile in the reaction system is 5-20% (such as 10%);
[0056] The reaction system is composed of 5 mmol / L of substrate 4-(oxirane-2-yl)-1-butanol or 2-(3-phenyloxetane-3-yl)ethanol, 100 g / L of whole cells expressing limonene epoxide hydrolase LEH or its mutant, 1 g / L of lysozyme, 6 U / mL of DNase I (deoxyribonuclease), 5% acetonitrile as a cosolvent, and the balance is potassium phosphate buffer.
[0057] The invention uses directed evolution technology and methods to modify the limonene epoxide hydrolase LEH from Rhodococcus erythropolis DCL14, and obtains a series of mutants with enzyme activity for epoxy alcohols represented by 4-(oxirane-2-yl)-1-butanol. The mutant can efficiently asymmetric reduce and catalyze 4-(oxirane-2-yl)-1-butanol to generate (S)-(tetrahydro-2H-pyran-2-yl)methanol, and the mutant 2-(3-phenyloxetane-3-yl)ethanol synthesizes (S)-(3-phenyltetrahydrofuran-3-yl)methanol. The method has the advantages of high yield (yield up to 99%), high ee value, low coenzyme usage, no need to add additional enzymes such as glucose dehydrogenase for cofactor circulation, mild reaction conditions, simple operation, etc. Therefore, the invention has good industrial application prospects in biocatalytic preparation of chiral amine alcohol compounds. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 The invention discloses a limonene epoxide hydrolase LEH or a mutant thereof which catalyzes 4-(oxiran-2-yl)-1-butanol to generate (S)-(tetrahydro-2H-pyran-2-yl)methanol.
[0059] Figure 2 It is used to catalyze the synthesis of (S)-(3-phenyltetrahydrofuran-3-yl)methanol from 2-(3-phenyloxetane-3-yl)ethanol.
[0060] Figure 3 The invention relates to the synthesis of (S)-(1-benzyl-3-phenyltetrahydropyridin-3-yl)methanol from N-benzyl-2-(3-phenyloxetane-3-yl)ethylamine catalyzed by limonene epoxide hydrolase LEH or its mutant.
[0061] Figure 4 GC detection results of limonene epoxide hydrolase LEH or its mutants catalyzing 4-(oxiran-2-yl)-1-butanol to produce (S)-(tetrahydro-2H-pyran-2-yl)methanol.
[0062] Figure 5 The HPLC detection results of limonene epoxide hydrolase LEH or its mutants catalyzing the synthesis of (S)-(3-phenyltetrahydrofuran-3-yl)methanol from 2-(3-phenyloxetane-3-yl)ethanol. Among them, WT: LEH; M1: mutant Y53F / N55A / I80F / L114V / I116V; M2: mutant Y53F / N55A / I116V; M3: mutant Y53F / N55A / I80F / I116V.
[0063] Figure 6This is a graph showing the HPLC detection results of the synthesis of (S)-(1-benzyl-3-phenyltetrahydropyridin-3-yl)methanol from N-benzyl-2-(3-phenyloxetane-3-yl)ethylamine catalyzed by limonene epoxide hydrolase LEH or its mutants. DETAILED DESCRIPTION
[0064] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the examples are all commercially available unless otherwise specified. The following examples are provided to facilitate a better understanding of the present invention, but are not intended to limit the present invention.
[0065] The quantitative tests in the following examples were all repeated three times, and the results were averaged.
[0066] Example 1. Sequences of limonene epoxide hydrolase LEH and its mutants
[0067] The invention uses directed evolution technology and methods to modify the limonene epoxide hydrolase LEH from Rhodococcus erythropolis DCL14. 4-(2-oxirane-1-yl)-1-butanol is selected as a model substrate, and the FY53 / N55 site of the activated water molecule network of the limonene epoxide hydrolase LEH is destroyed to mutate it into a hydrophobic amino acid. The following mutants are obtained by screening through degenerate codon library construction.
[0068] The nucleotide sequence of the limonene epoxide hydrolase LEH in this embodiment is shown in SEQ ID No. 1 (GenBank: Y18005.1), and the amino acid sequence of the limonene epoxide hydrolase LEH is shown in SEQ ID NO. 2. The limonene epoxide hydrolase LEH in this embodiment is specifically any one of the following (1)-(10):
[0069] (1) Limonene epoxide hydrolase LEH mutant Y53L / N55P: a protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to leucine (L), and the 55th amino acid from asparagine (N) to proline (P), while keeping the other amino acid sequences unchanged;
[0070] (2) Limonene epoxide hydrolase LEH mutant Y53I / N55P: a protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to isoleucine (I), and the 55th amino acid from asparagine (N) to proline (P), while keeping the other amino acid sequences unchanged;
[0071] (3) Limonene epoxide hydrolase LEH mutant Y53V / N55P: a protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to valine (V), and the 55th amino acid from asparagine (N) to proline (P), while keeping the other amino acid sequences unchanged;
[0072] (4) Limonene epoxide hydrolase LEH mutant Y53I / N55A: a protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to isoleucine (I), and the 55th amino acid from asparagine (N) to alanine (A), while keeping the other amino acid sequences unchanged;
[0073] (5) Limonene epoxide hydrolase LEH mutant Y53F / N55P: a protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to phenylalanine (F), and the 55th amino acid from asparagine (N) to proline (P), while keeping the other amino acid sequences unchanged;
[0074] (6) Limonene epoxide hydrolase LEH mutant Y53F / N55A: a protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to phenylalanine (F), and the 55th amino acid from asparagine (N) to alanine (A), while keeping the other amino acid sequences unchanged;
[0075] (7) Limonene epoxide hydrolase LEH mutant Y53F / N55A / I80F / L114V / I116V: The 53rd amino acid of the limonene epoxide hydrolase LEH sequence is mutated from tyrosine (Y) to phenylalanine (F), and the 55th amino acid is mutated from asparagine (N) to alanine (A), and the 80th isoleucine (I) is mutated to phenylalanine (F), and the 114th leucine (L) is mutated to valine (V), and the 116th isoleucine (I) is mutated to valine (V). The protein is obtained by keeping the other amino acid sequences unchanged;
[0076] (8) Limonene epoxide hydrolase LEH mutant Y53F / N55A / I116V: Limonene epoxide hydrolase LEH mutant Y53F / N55A / I80F / I116V: The 53rd amino acid of the limonene epoxide hydrolase LEH sequence is mutated from tyrosine (Y) to phenylalanine (F), the 55th amino acid is mutated from asparagine (N) to alanine (A), and the 116th isoleucine (I) is mutated to valine (V). The protein is obtained by keeping the other amino acid sequences unchanged;
[0077] (9) Limonene epoxide hydrolase LEH mutant Y53F / N55A / I80F / I116V: A protein obtained by changing the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine (Y) to phenylalanine (F), the amino acid at position 55 from asparagine (N) to alanine (A), the isoleucine at position 80 (I) to phenylalanine (F), and the isoleucine at position 116 (I) to valine (V), while keeping the other amino acid sequences unchanged.
[0078] Example 2: Preparation of engineered bacteria containing limonene epoxide hydrolase LEH gene or its mutant
[0079] 1. Preparation of limonene epoxide hydrolase LEH genetic engineering strain
[0080] Limonene epoxide hydrolase LEH from Rhodococcus erythropolis DCL14 was expressed in Escherichia coli as a host cell, and its nucleotide sequence is SEQ ID No. 1 (GenBank: Y18005.1).
[0081] The target gene was linked to the pET22b plasmid through the NdeI and XhoI restriction sites to obtain a recombinant vector. The recombinant vector pET22b-ReLEH was transformed into E. coli BL21 (DE3) competent cells and cultured in the presence of ampicillin (A + ) in an LB solid plate and cultured for 12-16 h, and positive transformants were selected for colony PCR and DNA sequencing verification. The correct transformants were confirmed to be the limonene epoxide hydrolase LEH genetic engineering strain.
[0082] 2. Preparation of engineered strains of limonene epoxide hydrolase LEH gene mutants
[0083] The limonene epoxide hydrolase LEH gene mutant engineering strains of each limonene epoxide hydrolase LEH mutant in Example 1 were constructed respectively. The mutants of limonene epoxide hydrolase LEH were obtained by screening a mutant library constructed by designing degenerate primers, or by designing mutant primers. The sequences of the designed degenerate primers and mutant primers are shown in Tables 2 and 3.
[0084] Table 1 Primer sequences used for mutation library construction
[0085]
[0086]
[0087] Table 2 Mutants and primer sequences used
[0088]
[0089] The specific construction method is as follows:
[0090] 1. Construction of Y53 / N55 mutation library
[0091] Construction of Y53 / N55 mutation library Two rounds of PCR reactions were performed using the recombinant vector pET22b-ReLEH as a template and primers corresponding to each mutant. The specific sequences of the primers used to construct the mutation library are shown in Table 2:
[0092] The PCR reaction system and procedure are as follows:
[0093] The first round of PCR system was 50 μL, including the following components: template (150 ng / μL) 1 μL; 2× High-fidelity Master Mix 25 μL; ddH2O 22 μL; front primer F1 (10 μmol / L) 1 μL; rear primer R1 (10 μmol / L) 1 μL. The specific sequences of the primers used are shown in Table 1.
[0094] The first round of PCR program: pre-denaturation at 98°C for 2 minutes; denaturation at 98°C for 10 seconds; annealing at 55°C for 15 seconds; extension at 72°C for 30 seconds; final extension at 72°C for 5 minutes. The cycle was repeated 30 times.
[0095] The second round PCR system was 50 μL, including the following components: 1 μL of template (150 ng / μL); 25 μL of 2×High-fidelity Master Mix; 22 μL of ddH2O; and 2 μL of the first round PCR product.
[0096] The second round of PCR program: pre-denaturation at 98°C for 2 minutes; denaturation at 98°C for 10 seconds; annealing at 60°C for 15 seconds; extension at 72°C for 30 seconds; final extension at 72°C for 5 minutes. The cycle was repeated 30 times.
[0097] 2. I80 / V83 / L114 / I116 mutation library
[0098] The recombinant vector pET22b-ReLEH-Y53F / N55A was used as a template to construct I80 / V83 / L114 / I116. The specific sequences of the primers used for mutant library construction are shown in Table 3:
[0099] The PCR reaction system and procedure are as follows:
[0100] The first round of PCR amplification obtained the F2R2 product. The PCR system was 50 μL, including the following components: template (150 ng / μL) 1 μL; 2× High-fidelity Master Mix 25 μL; ddH2O 22 μL; front primer (10 μmol / L) 1 μL; rear primer (10 μmol / L) 1 μL. The specific sequences of the primers used are shown in Table 2.
[0101] The first round of PCR program: pre-denaturation at 98°C for 2 minutes; denaturation at 98°C for 10 seconds; annealing at 55°C for 15 seconds; extension at 72°C for 30 seconds; final extension at 72°C for 5 minutes. The cycle was repeated 30 times.
[0102] The PCR products were subjected to agarose gel electrophoresis, and the nucleic acid bands were separated and then excised and recovered. For specific steps, refer to the instructions of the agarose gel recovery kit.
[0103] The second round of PCR amplification obtained the target PCR product. The PCR system was 50 μL, including the following components: template (150 ng / μL) 1 μL; 2× High-fidelity Master Mix 25 μL; ddH2O 22 μL; first round PCR product 2 μL.
[0104] The second round of PCR program: pre-denaturation at 98°C for 2 minutes; denaturation at 98°C for 10 seconds; annealing at 55°C for 15 seconds; extension at 72°C for 3 minutes; final extension at 72°C for 5 minutes. The cycle was repeated 30 times.
[0105] After PCR, add 2 μL of DpnI enzyme to each reaction system, digest at 37°C for 2 hours, and take 1 μL to electroporate into E. coli BL21 (DE3) competent cells, put them in a 37°C incubator and culture them upside down for 12-16 hours. After transformants grow out, pick the transformants for sequencing verification. The transformants verified by sequencing are the engineered strains of the limonene epoxide hydrolase LEH gene mutant.
[0106] Example 3. Expression of limonene epoxide hydrolase LEH or its mutants and preparation of whole cells, crude enzyme solution and pure enzyme solution
[0107] The limonene epoxide hydrolase LEH gene or its mutant engineered strain prepared in Example 2 was induced to express. The recombinant E. coli BL21 (DE3) transformant containing the recombinant plasmid of limonene epoxide hydrolase LEH or its mutant was selected and placed in 5 mL LB liquid culture medium containing 100 μg / mL ampicillin, shaken at 37°C and 220 rpm overnight for 12 h, and then inoculated into TB liquid culture medium containing 5100 μg / mL ampicillin according to the volume percentage of 1% inoculation amount, and cultured at 37°C until OD 600When the pH value was 0.7, IPTG with a final concentration of 0.1 mmol / L was added, and the expression was induced at 20°C and 220 rpm for 12 hours, and then centrifuged at 4°C and 4,000 rpm for 10 minutes, and the precipitated bacteria were collected, and the collected bacteria were resuspended in potassium phosphate buffer (50 mmol / L, pH 7.4) to obtain the whole cells of limonene epoxide hydrolase LEH or its mutants, and then the bacterial cells were ultrasonically broken under ice bath conditions to obtain the ultrasonically broken samples or the samples after the cell walls were broken by lysozyme (i.e., the crude enzyme solution). The crude enzyme solution was centrifuged at 12,000 rpm and 4°C for 60 minutes to collect the supernatant, filtered with a 0.45 μm water filter membrane, and purified with an ATKA protein purifier. The chromatography column used was a HisTrap HP 5 mL pre-packed column (GE), item number 17524802. Loading and equilibration buffer A (50mmol / L potassium phosphate buffer, 0.5mol / L NaCl, 20mmol / L imidazole, pH 8.0); elution buffer B (50mmol / L potassium phosphate buffer, 0.5mol / L NaCl, 500mmol / L imidazole pH 8.0), elution flow rate 2mL / min; collect the eluate (i.e., pure enzyme solution).
[0108] Example 4: Crude enzyme solution of limonene epoxide hydrolase LEH or its mutant catalyzes the production of (S)-(tetrahydro-2H-pyran-2-yl)methanol from 4-(2-oxirane-1-yl)-butanol
[0109] The schematic diagram of using the crude enzyme solution of limonene epoxide hydrolase LEH or its mutant prepared in Example 3 to catalyze the production of (S)-(tetrahydro-2H-pyran-2-yl)methanol from 4-(oxirane-2-yl)-1-butanol is shown in FIG. Figure 1 shown.
[0110] The crude enzyme solution catalyzed reaction was carried out using the following asymmetric reduction reaction system:
[0111] The asymmetric reduction reaction system is composed of the following: substrate 4-(2-oxirane-1-yl)-1-butanol (0.05 mol / L), 5% by volume acetonitrile as a cosolvent, 100 g / L of whole cells expressing limonene epoxide hydrolase LEH or its mutant, 1 g / L of lysozyme, 6 U / mL of DNase I (deoxyribonuclease), and the balance is potassium phosphate buffer.
[0112] The asymmetric reduction reaction was carried out at 30°C for 12 hours.
[0113] After the reaction is completed, the conversion rate is calculated and the stereoselectivity is analyzed. The specific method is as follows:
[0114] The above reaction solution was added to an equal volume of isobutanol (x3) and suspended, centrifuged at 12,000 rpm for 2 minutes, the supernatant was aspirated, the organic phases were combined, dried over anhydrous sodium sulfate, filtered through a filter membrane, and then the reaction was detected by GC or HPLC.
[0115] The GC detection method is as follows:
[0116] Instrument: Shimadzu gas phase GC-2030; chromatographic column: HYDRODEXβ-TBDAc 25m*0.25mm ID; flow rate: 1ml / min carrier gas: N2; split: 30:1 injection volume: 1ul; SPL1: 220℃; FID1: 230℃; heating program: 110℃, 10℃ / min, 135℃, 2min, 10℃ / min, 200℃, 4min. HPLC detection conditions: chromatographic column: Chiralpark AD-H (250×4.6mm, 5μm); detection wavelength 220nm, column temperature: 30℃, flow rate: 1mL / min, sample volume: 2μL; mobile phase B: n-hexane, mobile phase C: isopropanol. Elution program: 98%B / 2%C, run for 40 minutes. The detection results are shown in Table 3.
[0117] Table 3 Detection results of limonene epoxide hydrolase LEH or mutant crude enzyme solution catalyzing 4-(2-oxirane-1-yl)-1-butanol
[0118]
[0119] Note: er=A in the table S :A R :A S : The peak area value of (S)-(tetrahydro-2H-pyran-2-yl)methanol obtained by liquid chromatography analysis; A R : Peak area value of (R)-(tetrahydro-2H-pyran-2-yl)methanol obtained by liquid chromatography analysis.
[0120] Example 5: Synthesis of (S)-(3-phenyltetrahydrofuran-3-yl)methanol from crude enzyme solution of limonene epoxide hydrolase LEH or its mutants 2-(3-phenyloxetane-3-yl)ethanol
[0121] The schematic diagram of the synthesis of (S)-(3-phenyltetrahydrofuran-3-yl)methanol from 2-(3-phenyloxetane-3-yl)ethanol using the crude enzyme solution of limonene epoxide hydrolase LEH or its mutant prepared in Example 3 is shown in FIG. Figure 3 shown.
[0122] The asymmetric reduction reaction system is composed of the following: substrate 2-(3-phenyloxetane-3-yl)ethanol (0.05 mol / L), 5% by volume acetonitrile as a cosolvent, 100 g / L of whole cells expressing limonene epoxide hydrolase LEH or its mutant, 1 g / L of lysozyme, 6 U / mL of DNase I (deoxyribonuclease), and the balance is potassium phosphate buffer.
[0123] The reaction conditions are as in Example 4, and the test results are shown in Table 5.
[0124] Table 5 Detection results of limonene epoxide hydrolase LEH or mutants catalyzing 2-(3-phenyloxetane-3-yl)ethanol
[0125] Limonene epoxide hydrolase LEH and its mutants Conversion rate (%) ee(%) WT - - Y53L / N55P 33 76:24(S) Y53I / N55P 5 53:47(S) Y53V / N55P 9 56:44(S) Y53I / N55A 47 56:44(S) Y53F / N55P 80 64:36(S) Y53F / N55A 83 66:34(S) Y53F / N55A / I80F / L114V / I116V 8 86:14(S) Y53F / N55A / I116V 96 72:28(S) Y53F / N55A / I80F / I116V 68 87:13(S)
[0126] Note: er=A in the table S :A R :A S : The peak area value of (S)-2-(3-phenyloxetane-3-yl)ethanol obtained by liquid chromatography analysis; A R : Peak area value of (R)-2-(3-phenyloxetane-3-yl)ethanol obtained by liquid chromatography analysis.
[0127] Example 6: Catalysis of oxirane alcohol substrate by crude enzyme solution of limonene epoxide hydrolase LEH or its mutants
[0128] The crude enzyme solution of limonene epoxide hydrolase LEH or its mutant prepared in Example 3 catalyzes the reaction of oxirane alcohol substrates, namely 4-(oxirane-2-yl)-1-butanol (1a), 4-(3-methyloxirane-2-yl)-1-butanol (1b), and 4-(3,3-dimethyloxirane-2-yl)-1-butanol (1c). The corresponding products are (S)-(tetrahydro-2H-pyran-2-yl)methanol (2a), (S)-1-(tetrahydro-2H-pyran-2-yl)ethan-1-ol (2b), and (S)-2-(tetrahydro-2H-pyran-2-yl)propan-2-ol (2c).
[0129] The crude enzyme solution catalyzed reaction was carried out using the following asymmetric reduction reaction system:
[0130] The asymmetric reduction reaction system consists of: 5 mmol / L substrate, 100 g / L whole cells of limonene epoxide hydrolase LEH or its mutant, 5% by volume acetonitrile as a cosolvent, 100 g / L whole cells expressing limonene epoxide hydrolase LEH or its mutant, 1 g / L lysozyme, 6 U / mL of DNase I (deoxyribonuclease), and the balance is potassium phosphate buffer (pH 7.4).
[0131] Table 6 shows the GC detection method
[0132]
[0133] Note: a Chromatographic column: HYDRODEXβ-TBDAc 25m*0.25mm ID Flow rate: 1ml / min Carrier gas: N2 Split: 30:1 Injection volume: 1μL Split; SPL1: 220℃; FID1: 230℃; Heating program: 110℃, 10℃ / min, 135℃, 2min, 10℃ / min, 200℃, 4min. The test results are shown in Table 7 and Figure 5 As shown, it can be seen that the limonene epoxide hydrolase LEH mutant has good catalytic activity and enantiomeric selectivity for the substrate 4-(oxiran-2-yl)-1-butanol, and also has good catalytic activity for other oxirane alcohol substrates.
[0134] Table 7 Detection results of limonene epoxide hydrolase LEH and its mutants catalyzing oxirane alcohol substrates
[0135]
[0136] Example 8: Synthesis of (S)-(3-phenyltetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0137]
[0138] Similar to the method of Example 6: the substrate selected was 2-(3-phenyloxetane-3-yl)ethanol (5 mM) M2 (Y53F / N55A / I116V): conversion = 99%; er = 72:28; M3 (Y53F / N55A / I80F / I116V): conversion = 99%; er = 72:28; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =22.8min(minor)and t R =24.0min(major)].
[0139] 1H NMR (400MHz, CDCl3) δ7.38(t,J=7.5Hz,2H),7.29(t,J=7.3Hz,1H),7.22(d,J=7.3Hz,2H),4.25(d,J=8.6Hz,1H),4.05(dd,J=15 .9,7.9Hz,1H),4.04–3.89(m,1H),3.85(d,J=8.6Hz,1H),3.74–3.52(m,2H),2.45–2.29(m,1H),2.28–2.12(m,1H),1.92(s,1H).
[0140] 13 C NMR (100MHz, CDCl3) δ143.11,128.66,127.28,126.92,74.26,69.34,67.59,53.47,33.90.
[0141] HRMS(ESI):calcd for[M+H]+Chemical Formula:C11H14O2 178.0994; found178.0996.
[0142] Example 9: Synthesis of (S)-(3-(4-methylphenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0143]
[0144] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-methylphenyl)oxetane-3-yl)ethanol (5 mM); M2 (Y53F / N55A / I116V): conversion rate = 99%; er = 78:22; M3 (Y53F / N55A / I80F / I116V): conversion rate = 79%; er = 87:13; HPLC detection Daicel CHIRALCEL AD-H column (25 cm×0.46 cmID) [n-hexane / isopropanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =30.9min(minor)and t R =32.5min(major)].
[0145] 1H NMR (400MHz, CDCl3) δ7.19(d,J=7.9Hz,2H),7.11(d,J=8.1Hz,2H),4.18(d,J=8.5Hz,1H),4.01(q,J=7.8Hz,1H),3.91(dd,J=13 .0,8.2Hz,1H),3.80(d,J=8.5Hz,1H),3.62(s,2H),2.44(s,1H),2.37(s,3H),2.34–2.24(m,1H),2.17(dd,J=20.2,8.2Hz,1H).
[0146] 13 C NMR (100MHz, CDCl3) δ134.0,136.6,129.4,127.2,74.4,69.4,67.6,53.1,34.0,21.0.
[0147] HRMS(ESI):calcd for[M+H] + C12H16O2 192.1150; found 192.1155.
[0148] Example 10: Synthesis of (S)-(3-(4-methylphenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase mutant
[0149]
[0150] The method is similar to that of Example 6: the substrate selected is 2-(3-(3-methylphenyl)oxetane-3-yl)ethanol (5 mM); M2 (Y53F / N55A / I116V): conversion = 99%; er = 64:36; M3 (53F / N55A / I80F / I116V): conversion = 91%; er = 83:17; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 95:5, λ = 254 nm, flow rate: 1.0 mL / min; t S =13.4min(minor)and t R =15.2min(major)]].
[0151] 1H NMR (400MHz, CDCl3) δ7.26(t,J=7.5Hz,1H),7.10(d,J=7.5Hz,1H),7.02(d,J=9.3Hz,2H),4.20(d,J=8.5Hz,1H),4.01( t,J=7.6Hz,1H),3.93(dd,J=9.0,4.9Hz,1H),3.82(d,J=8.5Hz,1H),2.40(s,3H),2.36–2.27(m,1H),2.24–2.13(m,1H).
[0152] 13 C NMR (100MHz, CDCl3) δ138.1,128.4,128.1,127.5,124.4,74.2,69.0,67.5,53.3,33.9,21.6.
[0153] HRMS(ESI):calcd for[M+H] + C12H16O2 192.1150; found 192.1155.
[0154] Example 11: Synthesis of (S)-(3-(3,5-dimethylphenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0155]
[0156] The method is similar to that of Example 6: the substrate selected is 2-(3-(3,5-dimethylphenyl)oxetane-3-yl)ethanol (5 mM); M2 (Y53F / N55A / I116V): conversion rate = 99%; er = 64:36; M3 (Y53F / N55A / I80F / I116V): conversion rate = 91%; er = 81:19; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 95:5, λ = 254 nm, flow rate: 1.0 mL / min; t S =13.4min(minor)and t R =15.2min(major)].
[0157] 1H NMR (400MHz, CDCl3) δ6.95(s,1H),6.84(s,2H),4.24(d,J=8.5Hz,1H),4.06(q,J=7.9Hz,1H),3.95(td,J=8.9,5 .0Hz,1H),3.84(d,J=8.5Hz,1H),3.67(s,2H),2.37(s,6H),2.36–2.28(m,1H),2.27–2.10(m,1H),1.80(s,1H).
[0158] 13 C NMR (100MHz, CDCl3) δ143.0,143.0,138.1,128.6,125.1,74.3,69.3,67.5,53.3,33.9,21.5.
[0159] HRMS(ESI):calcd for[M+H] + C13H18O2206.1307; found 206.1308.
[0160] Example 12: Synthesis of (S)-(3-(4-ethylphenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0161]
[0162] The method is similar to that of Example 6: the substrate selected is 2-(4-ethylphenyl)oxetane-3-yl)ethanol (5 mM); M2 (Y53F / N55A / I116V): conversion rate = 99%; er = 76:24; M3 (Y53F / N55A / I80F / I116V): conversion rate = 78%; er = 90:19; HPLC detection Daicel CHIRALCEL AD-H column (25 cm×0.46 cmID) [n-hexane / ethanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =12.2min(minor)and t R =14.4min(major)];
[0163] 1H NMR (400MHz, CDCl3) δ7.22(d,J=8.2Hz,2H),7.15(d,J=8.2Hz,2H),4.26(d,J= 8.5Hz,1H),4.07(dd,J=15.9,7.9Hz,1H),3.95(td,J=8.9,5.1Hz,1H),3.85(d, J=8.6Hz,1H),3.69(s,2H),2.67(q,J=7.6Hz,2H),2.35(ddd,J=12.8,7.8,5.1H z,1H),2.21(ddd,J=12.4,9.2,7.3Hz,1H),1.58(s,1H),1.27(t,J=7.6Hz,3H). 13 C NMR(100MHz, CDCl3)δ142.8,140.3,128.1,127.2,74.4,69.3,67.6,53.1,34.0,28.4,15.6.; HRMS(ESI):calcd for[M+H] + C13H18O2206.1307; found 206.1308.
[0164] Example 13: Synthesis of (S)-(3-(4-methoxyphenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0165]
[0166] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-methoxyphenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion = 99%; er = 79:21; M2 (Y53F / N55A / I80F / I116V): conversion = 90%; er = 88:12; HPLC detection Daicel CHIRALCEL AD-H column (25 cm×0.46 cmID) [n-hexane / isopropanol = 98:2, λ = 254 nm, flow rate: 1.0 mL / min; t S =47.0min(minor)and t R =48.0min(major)];
[0167] 1H NMR (400MHz, CDCl3) δ7.15(d,J=8.7Hz,2H),6.92(d,J=8.7Hz,2H),4.22(d,J=8.5Hz,1H),4.10–4.00(m,1H),3.94(td,J=8.9,5.0H z,1H),3.83(s,3H),3.82(d,J=7.7Hz,1H),3.69–3.61(m,2H),2.32(ddd,J=12.6,7.8,5.1Hz,1H),2.24–2.11(m,1H),1.82(s,1H). 13 C NMR(100MHz, CDCl3)δ158.4,135.2,128.3,114.0,74.4,69.1,67.6,55.3,52.7,34.1; HRMS(ESI):calcd for[M+H] + C12H16O3208.1099; found 208.1102.
[0168] Example 14: Synthesis of (S)-(3-(4-methylthiophenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0169]
[0170] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-methylthiophenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 97%; er = 78:22; M2 (Y53F / N55A / I80F / I116V): conversion rate = 64%; er = 89:11; HPLC detection Daicel CHIRALCEL AD-H column (25 cm×0.46 cmID) [n-hexane / ethanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =22.0min(minor)and t R =23.1min(major)];
[0171] 1H NMR (400MHz, CDCl3) δ7.27(d,J=8.3Hz,1H),7.15(d,J=8.4Hz,1H),4.22(d,J=8.6Hz,1H),4.05(q,J=7.9Hz,1H),3.94(td,J=8.9, 5.1Hz,1H),3.83(d,J=8.6Hz,1H),3.67(s,1H),2.51(s,1H),2.33(ddd,J=12.7,7.8,5.1Hz,1H),2.24–2.06(m,1H),1.67(s,1H). 13 C NMR(100MHz, CDCl3)δ140.0,140.0,137.0,137.0,127.8,126.9,74.3,69.1,67.6,53.1,34.0,15.9; HRMS(ESI):calcd for[M+H] + C12H16O2S224.0871; found 224.0871.
[0172] Example 15: Synthesis of (S)-(3-(4-naphthyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0173]
[0174] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-naphthyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 87%; er = 82:18; M2 (Y53F / N55A / I80F / I116V): conversion rate = 78%; er = 90:10; HPLC detection Daicel CHIRALCEL AD-H column (25 cm×0.46 cmID) [n-hexane / ethanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =34min(minor)and t R =36min(major)];
[0175] 1H NMR (400MHz, CDCl3) δ7.87(dd,J=8.2,2.8Hz,3H),7.67(s,1H),7.58–7.47(m,2H),7.36(d,J=8.5Hz,1H),4.33(d,J=8.6H z,1H),4.10(dd,J=15.9,7.9Hz,1H),4.03–3.94(m,2H),3.77(s,2H),2.50–2.39(m,1H),2.36–2.26(m,1H),1.82(s,1H). 13 C NMR (100MHz, CDCl3) δ140.4,133.2,132.3,128.5,128.5,127.9,127.6,126.4 ,126.0,125.9,125.5,74.3,69.1,69.1,67.7,53.6,34.1.;HRMS(ESI):calcd for[M+H] + C15H17O2229.1223; found 229.1224.
[0176] Example 16: Synthesis of (S)-(3-(4-fluorophenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0177]
[0178] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-fluorophenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion = 99%; er = 71:29; M2 (Y53F / N55A / I80F / I116V): conversion = 79%; er = 84:15; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 93:7, λ = 254 nm, flow rate: 1.0 mL / min; t S =16.5min(minor)and t R =17.9min(major)];
[0179] 1H NMR (400MHz, CDCl3) δ7.25–7.16(m,2H),7.08(t,J=8.6Hz,2H),4.25(d,J=8.6Hz,1H),4.07(q,J=7.9Hz,1H),3.98( dd,J=8.9,5.0Hz,1H),3.83(d,J=8.5Hz,1H),3.74–3.64(m,2H),2.46–2.28(m,1H),2.26–2.13(m,1H),1.74(s,1H). 13 C NMR (100MHz, CDCl3) δ161.6 (d, J = 245.6Hz), 139.0 (d, J = 3.3Hz), 128.8 (d, J = 7.9Hz) ,115.4(d,J=21.1Hz),74.3,68.9(d,J=0.6Hz),67.6,52.9,34.2; HRMS(ESI):calcd for[M+H] + C11H14FO2197.0972; found 197.0975.
[0180] Example 17: Synthesis of (S)-(3-(4-chlorophenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0181]
[0182] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-chlorophenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 99%; er = 73:27; M2 (Y53F / N55A / I80F / I116V): conversion rate = 98%; er = 89:11; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 93:7,, λ = 254 nm, flow rate: 1.0 mL / min; t S =15.4min(major)and t R =17.0min(minor)];
[0183] 1H NMR (400MHz, CDCl3) δ7.32(d,J=7.3Hz,2H),7.13(d,J=7.3Hz,2H),4.19–4.08(m,1H),4.01–3.93(m,1H) ,3.92–3.84(m,1H),3.79–3.70(m,1H),3.58(s,2H),2.53(s,1H),2.30–2.18(m,1H),2.17–2.03(m,1H). 13 C NMR(100MHz, CDCl3)δ142.0,132.6,128.7,128.6,74.0,68.5,67.5,53.0,34.0:HRMS(ESI):calcd for[M+H] + C11H14ClO2 212.0604; found212.0604.
[0184] Example 18: Synthesis of (S)-(3-(4-bromophenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0185]
[0186] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-chlorophenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 99%; er = 77:23; M2 (Y53F / N55A / I80F / I116V): conversion rate = 59%; er = 89:11; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 93:7,, λ = 254 nm, flow rate: 1.0 mL / min; t S =16.2min(major)and t R =18.1min(minor)];
[0187] 1 H NMR (400MHz, CDCl3) δ7.51(d,J=8.3Hz,2H),7.12(d,J=8.4Hz,2H),4.22(d,J=8.6Hz,1H),4.05(q,J=7.9Hz,1 H),4.00–3.91(m,1H),3.81(d,J=8.6Hz,1H),3.68(s,2H),2.48–2.24(m,1H),2.22–2.10(m,1H),1.83(s,1H). 13C NMR(100MHz, CDCl3)δ142.5,131.7,129.2,120.9,74.1,68.8,67.6,53.2,34.1.; HRMS(ESI):calcd for[M+H] + C11H14BrO2256.0099; found 256.0098;
[0188] Example 19: Synthesis of (S)-(3-(4-trifluoromethylphenyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0189]
[0190] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-chlorophenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 99%; er = 77:23; M2 (Y53F / N55A / I80F / I116V): conversion rate = 59%; er = 89:11; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 93:7,, λ = 254 nm, flow rate: 1.0 mL / min; t S =17.1min(major)and t R =19.4min(minor)];
[0191] 1 H NMR (400MHz, CDCl3) δ7.61(d,J=8.1Hz,2H),7.32(d,J=8.0Hz,2H),4.18(d,J=8.6Hz,1H),3.98(d,J=7.7Hz,1H) ,3.89(d,J=4.9Hz,1H),3.78(d,J=8.6Hz,1H),3.62(s,2H),2.71(s,1H),2.34–2.24(m,1H),2.20–2.07(m,1H). 13 C NMR (100MHz, CDCl3) δ147.7 (d, J = 1.3Hz), 129.0 (q, J = 32.5Hz), 125.3 (q, J = 3.8Hz), 124.2 (q, J = 271.9Hz), 73.8, 68.3, 67.4, 53.4, 34.0.; HRMS (ESI): calcd for[M+H] + C12H13F3O2246.0868; found246.0868.
[0192] Example 20: Synthesis of (S)-(3-(4-benzyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0193]
[0194] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-chlorophenyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 99%; er = 95:5; M2 (Y53F / N55A / I80F / I116V): conversion rate = 59%; er = 96:4; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 97:3,, λ = 254 nm, flow rate: 1.0 mL / min; t S =11.7min(major)and t R =13.3min(minor)];
[0195] 1 H NMR (400MHz, CDCl3) δ7.34(t,J=7.1Hz,2H),7.27(t,J=8.5Hz,3H),4.02–3.81(m,2H),3.73(d,J=8.8Hz,1H),3.64 (d,J=8.8Hz,1H),3.50(s,2H),2.86(dd,J=35.4,13.4Hz,2H),1.97(s,1H),1.92–1.81(m,1H),1.80–1.70(m,1H). 13 C NMR(100MHz, CDCl3)δ138.4,130.1,128.3,126.4,75.0,67.7,65.7,49.1,39.9,33.8.; HRMS(ESI):calcd for[M+H] + C13H18O2206.1307; found 206.1308.
[0196] Example 21: Synthesis of (S)-(3-(4-ethyl)tetrahydrofuran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0197]
[0198] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-ethyl)oxetane-3-yl)ethanol (5 mM); M1 (Y53F / N55A / I116V): conversion = 79%; er = 85:15; M2 (Y53F / N55A / I80F / I116V): conversion = 59%; er = 96:4; chromatography column: HYDRODEXβ-TBDAc 25m*0.25mm ID; flow rate: 1 ml / min; carrier gas: N2; split: 30:1; injection volume: 1 μL split; SPL1: 220°C; FID1: 230°C; heating program: 110°C, 10°C / min, 135°C, 2min, 10°C / min, 200°C, 4min; t S =8.8min(major)and t R =9.2min(minor)];
[0199] 1 H NMR(400MHz, CDCl3)δδ3.99–3.78(m,2H),3.73(d,J=8.8Hz,1H),3.61–3.49(m,2H),3.44( d,J=8.8Hz,1H),2.45(s,1H),1.84–1.64(m,2H),1.66–1.40(m,2H),0.93(t,J=7.5Hz,3H). 13 C NMR(100MHz, CDCl3)δ140.3,140.3,140.3,136.4,136.3,129.2,127.2,74.3,69.0,67.6,53.0,34.0,21.0; HRMS(ESI):calcd for[M+H] + C7H14O2130.0994; found130.0999.
[0200] Example 22: Synthesis of (S)-(3-phenyltetrahydro-2H-pyran-3-yl)methanol catalyzed by crude enzyme solution of limonene epoxide hydrolase LEH mutant
[0201]
[0202] The method is similar to that of Example 6: the substrate selected is 2-(3-(4-chlorophenyl)oxetane-3-yl)propanol (5 mM); M1 (Y53F / N55A / I116V): conversion rate = 67%; er = 83:17; M2 (Y53F / N55A / I80F / I116V): conversion rate = 54%; er = 90:10; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 93:7,, λ = 254 nm, flow rate: 1.0 mL / min; t S =12.3min(major)and t R =13.5min(minor)];
[0203] 1 H NMR (400MHz, CDCl3) δ7.46–7.37(m,4H),7.28(ddd,J=8.4,5.7,2.5Hz,1H),4.04(d,J=11.7Hz,1H),3.93(d,J=11.7Hz,1H),3. 86–3.72(m,3H),3.64(ddd,J=11.1,7.4,3.6Hz,1H),2.12–1.89(m,2H),1.73(dtd,J=15.8,8.0,4.1Hz,1H),1.63–1.49(m,2H). 13 C NMR(100MHz, CDCl3)δ142.7,128.7,126.9,126.7,72.8,68.6,68.4,42.9,30.5,22.4; HRMS(ESI):calcd for[M+H] + C12H16O2192.1150; found 192.1153;
[0204] Example 23, Preparation of (1-benzyl-3-phenyltetrahydropyridin-3-yl)methanol:
[0205]
[0206] Similar to the method of Example 6: the selected substrate is N--2-(3-phenyloxetane-3-yl)ethylamine (5mM), the limonene epoxide hydrolase LEH mutant is M4 (Y53F / N55A), and the conversion rate is 68%. HPLC detection, DaicelCHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol (0.1% diethylamine) = 98:2, λ = 254nm, flow rate: 1.0mL / min; t S=17.237min(major)and t R =18.5min(minor)
[0207] 1 H NMR (400MHz, CDCl3) δ7.44–7.33(m,7H),7.27(t,J=7.3Hz,1H),7.22(d,J=7.2Hz,2H),3.79–3.62(m,3H),3.56(s,1H),3 .46(d,J=8.7Hz,1H),3.33–3.21(m,1H),2.73(dd,J=8.8,1.7Hz,1H),2.63–2.52(m,1H),2.46–2.25(m,2H),1.31(s,1H).
[0208] 13 C NMR (100MHz, CDCl3)δδ145.0,138.2,128.7,128.6,128.4,127.4,126.7,126.5,75.6,63.6,60.1,53.8,50.8,33.5.HRMS(ESI):calcd for[M+H]+ChemicalFormula:C11H14O2 178.0994; found 178.0996.
[0209] Example 24, Preparation of (1-allyl-3-phenyltetrahydropyridin-3-yl)methanol:
[0210]
[0211] Similar to the method of Example 6: the selected substrate is N-allyl-2-(3-phenyloxetane-3-yl)ethylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 94%; er = 90:10; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 98:2,,λ = 254nm, flow rate: 1.0mL / min; t S =10.7min(major)and t R =11.9min(minor).
[0212] 1H NMR(400MHz, CDCl3)δδ7.35(t,J=7.5Hz,2H),7.30–7.25(m,1H),7.22(d,J=7.2H z,2H),5.96(tt,J=12.8,6.5Hz,1H),5.38–5.12(m,2H),4.39(s,1H),3.75(d,J=1 0.1Hz,1H),3.65–3.48(m,2H),3.31(td,J=8.9,3.4Hz,1H),3.20(d,J=6.4Hz,2H) ,2.70(d,J=9.2Hz,1H),2.58–2.47(m,1H),2.44–2.35(m,1H),2.34–2.24(m,1H). 13 C NMR (100MHz, CDCl3) δ144.8,134.5,128.5,128.4,126.7,126.6,118.1,75.0,63.2,58.4,53.5,50.9,33.5.HRMS(ESI):calcd for[M+H]+Chemical Formula:C14H19NO217.1467; found217.1469.
[0213] Example 25, Preparation of (1-propargyl-3-phenyltetrahydropyridin-3-yl)methanol:
[0214]
[0215] The method is similar to that of Example 1: the substrate selected is N-propargyl-2-(3-phenyloxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 94%; er = 90:10; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 98:2,, λ = 254 nm, flow rate: 1.0 mL / min; t S =10.7min(major)and t R =11.9min(minor)
[0216] 1H NMR(400MHz, CDCl3)δδ7.37(t,J=7.5Hz,2H),7.30–7.22(m,3H),4.03(s,1H),3.74(d,J=10.1Hz,1H),3.59(d,J=10.2Hz,1H),3.56–3.45(m,2H),3.3 8(d,J=8.8Hz,1H),3.16(td,J=8.8,3.8Hz,1H),2.97(d,J=8.8Hz,1H),2.6 7(dd,J=16.8,9.5Hz,1H),2.49(dt,J=15.8,8.1Hz,1H),2.39–2.22(m,2H). 13 C NMR(100MHz, CDCl3)δ145.0,128.4,126.8,126.6,78.3,74.5,73.5,61.4,51.6,51.2,42.4,33.7.HRMS(ESI):calcd for[M+H] + C14H17NO 215.1310; found 215.1310.
[0217] Example 26, Preparation of (1-n-butyl-3-phenyltetrahydropyridin-3-yl)methanol:
[0218]
[0219] The method is similar to that of Example 1: the substrate selected is N-n-butyl-2-(3-phenyloxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion rate = 98%; er = 96:4; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 98:2, λ = 254 nm, flow rate: 1.0 mL / min; t S =13.5min(major)and t R =14.7min(minor).
[0220] 1H NMR (400MHz, CDCl3) δδ7.36 (t, J = 7.5Hz, 2H), 7.27 (d, J = 7.1Hz, 1H), 7.23 (d, J = 7. 4Hz,2H),4.83(s,1H),3.76(d,J=10.0Hz,1H),3.56(d,J=9.4Hz,2H),3.43–3.31(m ,1H),2.72(dd,J=8.9,1.8Hz,1H),2.62(dt,J=11.8,7.5Hz,1H),2.58–2.48(m,2H ),2.41–2.25(m,2H),1.67–1.55(m,2H),1.48–1.36(m,2H),0.98(t,J=7.3Hz,3H). 13 C NMR(100MHz, CDCl3)δ144.7,128.4,126.6,126.6,75.2,63.7,55.4,53.7,50.7,33.4,30.3,20.6,14.0.HRMS(ESI):calcd for[M+H] + C15H23NO233.1780; found 233.1780.
[0221] Example 27, Preparation of (1-phenyl-3-phenyltetrahydropyridine-3-yl)methanol:
[0222]
[0223] The method is similar to that of Example 1: the substrate selected is N-phenyl-2-(3-phenyloxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion rate = 98%; er = 99:1; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 98:2, λ = 254 nm, flow rate: 1.0 mL / min; t S =8.3min(major)and t R =11.0min(minor).
[0224] 1H NMR (400MHz, CDCl3) δ7.45(t,J=7.5Hz,2H),7.34(dd,J=15.9,7.8Hz,5H),6.78(t,J=7.2Hz,1H),6.70(d,J=8.0Hz,2H), 3.84(d,J=9.3Hz,1H),3.59(t,J=7.6Hz,2H),3.46(t,J=8.1Hz,1H),2.72–2.51(m,1H),2.41–2.19(m,1H),1.60(s,1H). 13 C NMR(100MHz, CDCl3)δ147.7,143.8,129.3,128.7,127.0,126.9,116.0,111.8,69.3,54.8,51.8,46.6,32.3.HRMS(ESI):calcd for[M+H] + C17H19NO253.1467; found253.1467.
[0225] Example 28, Preparation of (1-p-tolyl-3-phenyltetrahydropyridin-3-yl)methanol:
[0226]
[0227] Similar to the method of Example 1: the selected substrate is N-p-tolyl-2-(3-phenyloxetane-3-yl)ethylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 99%; er = 99:1; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 90:10, λ = 254nm, flow rate: 1.0mL / min; t S =11.2min(major)and t R =14.5min(minor).
[0228] 1 H NMR (400MHz, CDCl3) δ7.45(t,J=7.5Hz,2H),7.34(dd,J=15.9,7.8Hz,5H),6.78(t,J=7.2Hz,1H),6.70(d,J=8.0Hz,2H), 3.84(d,J=9.3Hz,1H),3.59(t,J=7.6Hz,2H),3.46(t,J=8.1Hz,1H),2.72–2.51(m,1H),2.41–2.19(m,1H),1.60(s,1H). 13C NMR(100MHz, CDCl3)δ147.7,143.8,129.3,128.7,127.0,126.9,116.0,111.8,69.3,54.8,51.8,46.6,32.3.HRMS(ESI):calcd for[M+H] + C18H21NO 267.1623; found 267.1623.
[0229] Example 29, Preparation of (1-p-chlorophenyl-3-phenyltetrahydropyridine-3-yl)methanol:
[0230]
[0231] The method is similar to that of Example 1: the substrate selected is N-p-chlorophenyl-2-(3-phenyloxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion rate = 98%; er = 99:1; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 98:2, λ = 254 nm, flow rate: 1.0 mL / min; t S =12.0min(major)and t R =14.5min(minor).
[0232] 1 H NMR (400MHz, CDCl3) δ7.45(t,J=7.5Hz,2H),7.34(dd,J=15.9,7.8Hz,5H),6.78(t,J=7.2Hz,1H),6.70(d,J=8.0Hz,2H), 3.84(d,J=9.3Hz,1H),3.59(t,J=7.6Hz,2H),3.46(t,J=8.1Hz,1H),2.72–2.51(m,1H),2.41–2.19(m,1H),1.60(s,1H). 13 C NMR(100MHz, CDCl3)δ147.7,143.8,129.3,128.7,127.0,126.9,116.0,111.8,69.3,54.8,51.8,46.6,32.3.HRMS(ESI):calcd for[M+H] + C17H18ClNO 287.1077; found 287.1077.
[0233] Example 30, Preparation of (1-benzyl-3-(4-methylphenyl)tetrahydropyridin-3-yl)methanol:
[0234]
[0235] Similar to the method of Example 1: the selected substrate is N-benzyl-2-(3-(4-methylphenyl)oxetane-3-yl)ethylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 53%; er = 94:6; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 90:10, λ = 254nm, flow rate: 1.0mL / min; t S =6.6min(major)and t R =7.4min(minor).
[0236] 1 H NMR (400MHz, CDCl3) δ7.45–7.32(m,5H),7.19(d,J=8.0Hz,2H),7.13(d,J=8.2Hz,2H),3.79–3.69(m,3H),3.58(dd,J=9.9,1.8Hz,1H),3.51(s,1H), 3.46(d,J=8.8Hz,1H),3.27(td,J=8.7,2.7Hz,1H),2.72(dd,J=8.8,1.7Hz ,1H),2.55(dt,J=12.1,8.1Hz,1H),2.46–2.37(m,4H),2.36–2.27(m,1H). 13 C NMR (100MHz, CDCl3) δ141.9,138.2,136.1,129.1,128.7,128.6,127.4,126.6,75.5,63.7,60.1,53.8,50.5,33.6,21.0.HRMS(ESI):calcd for[M+H] + C19H23NO 281.1780; found 281.1780.
[0237] Example 31, Preparation of (1-benzyl-3-(3-methylphenyl)tetrahydropyridin-3-yl)methanol:
[0238]
[0239] Similar to the method of Example 1: the selected substrate is N-benzyl-2-(3-(3-methylphenyl)oxetane-3-yl)ethylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 89%; er = 97:3; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 90:10, λ = 254nm, flow rate: 1.0mL / min; t S =6.1min(major)and t R =7.7min(minor).
[0240] 1 H NMR (400MHz, CDCl3) δ7.45–7.29(m,5H),7.24(t,J=7.9Hz,1H),7.08(d,J=7.5Hz,1H),7.02(d,J=6.4Hz,2H),4.43(s,1H),3.80–3.67(m,3H ),3.56(d,J=9.9Hz,1H),3.45(d,J=8.8Hz,1H),3.26(dd,J=12.3,5.3Hz,1H),2.72(d,J=8.8Hz,1H),2.59–2.48(m,1H),2.43–2.26(m,5H). 13 C NMR (100MHz, CDCl3) δ144.9,138.3,137.9,128.7,128.6,128.2,127.4,124.6,75.6,63.6,60.1,53.8,50.7,33.5,21.5.HRMS(ESI):calcd for[M+H] + C19H23NO 281.1780; found 281.1780.
[0241] Example 32, Preparation of (1-benzyl-3-(3,5-xylyl)tetrahydropyridin-3-yl)methanol:
[0242]
[0243] Similar to the method of Example 1: the selected substrate is N-benzyl-2-(3-(3,5-xylyl)oxetane-3-yl)ethylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 69%; er = 93:7; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 90:10, λ = 254nm, flow rate: 1.0mL / min; t S =5.1min(major)and t R =5.9min(minor).
[0244] 1 H NMR (400MHz, CDCl3) δ7.46–7.38(m,4H),7.37–7.32(m,1H),6.93(s,1H),6.84(s,2H),3.78–3.69(m,3H),3.57(dd,J=9.9,1.9Hz,1H),3.4 4(d,J=8.8Hz,1H),3.29–3.22(m,1H),2.71(dd,J=8.8,1.9Hz,1H),2.59–2.48(m,1H),2.43–2.37(m,1H),2.36(s,6H),2.34–2.26(m,1H). 13 C NMR (100MHz, CDCl3) δ144.9,138.3,137.9,128.7,128.6,128.2,127.4,124.6,75.6,63.6,60.1,53.8,50.7,33.5,21.5.HRMS(ESI):calcd for[M+H] + C20H25NO295.1936; found 295.1939.
[0245] Example 33, Preparation of (1-allyl-3-(4-ethylphenyl)tetrahydropyridin-3-yl)methanol:
[0246]
[0247] The method of Example 1 is similar: the substrate selected is N-allyl-2-(3-(4-ethylphenyl)oxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 73%; er = 85:15; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 90:10, λ = 254 nm, flow rate: 1.0 mL / min; t S =10.0min(major)and t R =11.9min(minor).
[0248] 1 H NMR(400MHz, CDCl3) δ7.17(dd,J=20.3,8.2Hz,4H),6.13–5.83(m,1H),5.35–5.12(m,2H),4.52(s,1H),3.75(d,J=10.0Hz,1H),3.64–3 .46(m,2H),3.37–3.25(m,1H),3.19(d,J=6.4Hz,2H),2.74–2.63(m,3H),2.56–2.48(m,1H),2.44–2.21(m,2H),1.27(t,J=7.6Hz,3H). 13 C NMR (100MHz, CDCl3) δ142.5,142.1,134.8,127.9,126.6,117.8,75.2,63.4,58.4,53.6,50.5,33.5,28.4,15.6.HRMS(ESI):calcd for[M+H] + C16H23NO245.1780; found 245.1780
[0249] Example 34, Preparation of (1-benzyl-3-(4-methoxyphenyl)tetrahydropyridin-3-yl)methanol:
[0250]
[0251] The method of Example 1 is similar: the substrate selected is N-benzyl-2-(3-(4-methoxyphenyl)oxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 83%; er = 98:2; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 90:10, λ = 254 nm, flow rate: 1.0 mL / min; t S =9.6min(major)and t R =10.5min(minor).
[0252] 1 H NMR(400MHz, CDCl3)δδ7.48–7.31(m,2H),7.19–7.10(m,1H),6.94–6.86(m,1H),3.83(s,1H),3.75–3.66(m,1H),3.54(dd,J=9.9,1.9Hz,1H),3.49 (s,1H),3.42(d,J=8.8Hz,1H),3.24(td,J=8.7,3.0Hz,1H),2.69(dd,J=8 .8,1.8Hz,1H),2.58–2.47(m,1H),2.44–2.36(m,1H),2.32–2.24(m,1H). 13 C NMR (100MHz, CDCl3) δ158.1,138.2,137.1,128.7,128.6,127.7,127.4,113.8,75.4,63.8,60.1,55.3,53.8,50.1,33.7.HRMS(ESI):calcdfor[M+H] + C19H23NO2 297.1729; found 297.1729.
[0253] Example 35, Preparation of (1-allyl-3-(4-ethylphenyl)tetrahydropyridin-3-yl)methanol:
[0254]
[0255] The method of Example 1 is similar: the substrate selected is N-benzyl-2-(3-(3,5-xylyl)oxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 73%; er = 89:11; HPLC detection Daicel CHIRALCEL AD-H column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 90:10, λ = 254 nm, flow rate: 1.0 mL / min; t S =20.6min(major)and t R =20.8min(minor).
[0256] 1 H NMR (400MHz,CDCl3) 1 H NMR(400MHz, CDCl3)δδ7.48–7.31(m,2H),7.19–7.10(m,1H),6.94–6.86(m,1H),3.83(s,1H),3.75–3.66(m,1H),3.54(dd,J=9.9,1.9Hz,1H),3.49 (s,1H),3.42(d,J=8.8Hz,1H),3.24(td,J=8.7,3.0Hz,1H),2.69(dd,J=8 .8,1.8Hz,1H),2.58–2.47(m,1H),2.44–2.36(m,1H),2.32–2.24(m,1H). 13 C NMR(100MHz, CDCl3)δ141.8,136.5,134.9,127.2,126.8,117.6,75.0,63.3,58.4,53.5,50.4,33.5,16.0.HRMS(ESI):calcd for[M+H] + C15H21NOS263.1344; found 263.1348.
[0257] Example 36, Preparation of (1-benzyl-3-(p-fluorophenyl)tetrahydropyridin-3-yl)methanol:
[0258]
[0259] The method of Example 1 is similar: the selected substrate is N-benzyl-2-(3-(p-fluorophenyl)oxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 61%; er = 94:6; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =14.9min(major)and t R =16.5min(minor).
[0260] 1 H NMR (400MHz, CDCl3) δ7.44–7.32(m,5H),7.21–7.14(m,2H),7.03(t,J=8.7Hz,2H),3.75–3.65(m,3H),3.56–3.49(m,1H),3.41(d,J=8.8Hz,1 H),3.25(td,J=8.9,3.0Hz,1H),2.69(dd,J=8.8,1.8Hz,1H),2.53(dt,J=12.2,8.1Hz,1H),2.41(dd,J=17.0,9.3Hz,1H),2.31–2.22(m,1H). 13 C NMR (100MHz, CDCl3) δ161.4 (d, J = 245.2Hz), 140.7 (d, J = 3.2Hz), 138.0, 128.7, 128.6, 128.2 (d ,J=7.9Hz),127.4,115.1(d,J=21.1Hz),75.4,63.6,60.0,53.7,50.3,33.6.HRMS(ESI):calcd for[M+H] + C18H20FNO 285.1529; found285.15332.
[0261] Example 37, Preparation of (1-benzyl-3-(p-chlorophenyl)tetrahydropyridin-3-yl)methanol:
[0262]
[0263] The method of Example 1 is similar: the selected substrate is N-benzyl-2-(4-(p-chlorophenyl)oxetane-3-yl)ethylamine (5 mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 57%; er = 91:9; HPLC detection Daicel CHIRALCEL IC column (25 cm × 0.46 cm ID) [n-hexane / isopropanol = 97:3, λ = 254 nm, flow rate: 1.0 mL / min; t S =15.5min(major)and t R =18.7min(minor).
[0264] 1 H NMR(400MHz, CDCl3)δδ7.43–7.29(m,7H),7.14(d,J=8.4Hz,2H),3.76–3.64(m,3H),3.53(dd,J=10.2,1.7Hz,1H),3.40(d,J=8.8Hz,1H), 3.25(td,J=8.8,3.0Hz,1H),2.67(dd,J=8.8,1.5Hz,1H),2.52(dt,J=12.2,8.1Hz,1H),2.41(dd,J=17.0,9.2Hz,1H),2.29–2.20(m,1H). 13 C NMR (100MHz, CDCl3) δ143.5,138.1,132.4,128.7,128.6,128.5,128.1,127.4,75.2,63.4,60.0,53.7,50.5,33.5.HRMS(ESI):calcd for[M+H] + C18H20ClNO301.1233; found 301.1233.
[0265] Example 38, Preparation of (1-benzyl-3-phenylpiperidin-3-yl)methanol:
[0266]
[0267] The method of Example 1 is similar: the substrate selected is N-benzyl-2-(4-phenyloxetane-3-yl)propylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 98%; er = 99:1; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 98:2, λ = 254nm, flow rate: 1.0mL / min; t S=27.8min(major)and t R =28.9min(minor).
[0268] 1 H NMR (400MHz, CDCl3) δ7.43–7.29(m,7H),7.14(d,J=8.4Hz,2H),3.76–3.64(m,3H),3.53(dd,J=10.2,1.7Hz,1H),3.40(d,J=8.8Hz,1H), 3.25(td,J=8.8,3.0Hz,1H),2.67(dd,J=8.8,1.5Hz,1H),2.52(dt,J=12.2,8.1Hz,1H),2.41(dd,J=17.0,9.2Hz,1H),2.29–2.20(m,1H). 13 C NMR (100MHz, CDCl3) δ143.5,138.1,132.4,128.7,128.6,128.5,128.1,127.4,65.3,64.6,60.3,57.335.1,32.7,21.1.HRMS(ESI):calcd for[M+H] + C18H20ClNO 281.1780; found 281.1782.
[0269] Example 39, Preparation of (1-benzyl-3-benzylpiperidin-3-yl)methanol:
[0270]
[0271] The method of Example 1 is similar: the substrate selected is N-benzyl-2-(benzyloxetane-3-yl)propylamine (5mM) limonene epoxide hydrolase LEH mutant M4 (Y53F / N55A): conversion = 67%; er = 71:29; HPLC detection Daicel CHIRALCEL AD-H column (25cm×0.46cm ID) [n-hexane / isopropanol = 98:2, λ = 254nm, flow rate: 1.0mL / min; t S =24.6min(major)and t R =26.8min(minor).
[0272] 1H NMR (400MHz, CDCl3) δ7.44–7.18(m,10H),4.21(d,1H,J=13.7Hz),3.94(d,1H,J=10.8Hz),3.28(d,1H,J=13.7Hz),3.23(d,1H,J =13.2Hz),3.17(d,1H,J=10.1Hz),2.85(m,1H),2.75(d,1H,J=13.5Hz),2.54(ddd,1H,J=12.1,3.0,3.0Hz),1.78–1.39(m,6H); 13 CNMR(100MHz, CDCl3)δ139.3,137.7,130.1,129.5,129.1,128.5,126.5(d),126.3,65.2,60.6,53.0,46.3,37.1,29.7,25.8,20.6.HRMS(ESI):calcd for[M+H] + C20H25NO295.1936; found 295.1938. <110> Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences <120> Limonene epoxide hydrolase mutants and their catalytic synthesis of chiral oxygen / nitrogen-heterocyclic compounds <160> 2 <210> 1 <211> 450 <212> DNA <213> Rhodococcus erythropoli <400> 1 ATGACATCAAAGATCGAACAACCTCGCTGGGCGTCCAAGGACAGTGCCGCCGGCGCTGCCTCGACTCCGGACGAAAAGATCGTTCTGGAGTTCATGGACGCACTGACCAGTAATGATGCTGCAAAACTCATTGAGTACTTTGCAGAAGACACGATGTACCAGAACATGCCACTCCCCCCTGCATACGGCCGCGACGCCGTCGAGCAAACTCTGGCTGGCCTGTTCACCGTCATGAGCATCGATGCGGTGGAGACGTTCCATATCGGCTCGAGTAACGGACTTGTGTACACCGAACGTGTCGATGTCCTACGCGCACTACCCACCGGCAAGAGCTACAACCTGTCAATCCTCGGAGTCTTCCAGCTCACCGAGGGCAAGATTACGGGTTGGCGTGACTACTTCGATCTGCGCGAATTCGAAGAAGCTGTCGACCTTCCCCTCCGCGGCTAA 450 <210> 2 <211> 149 <212> PRT <213> Artificial Sequence <400> 2 MTSKIEQPRWASKDSAAGAASTPDEKIVLEFMDALTSNDAAKLIEYFAEDTMYQNMPLPPAYGRDAVEQTLAGLFTVMSIDAVETFHIGSSNGLVYTERVDVLRALPTGKSYNLSILGVFQLTEGKITGWRDYFDLREFEEAVDLPLRG 149
Claims
1. A limonene epoxide hydrolase LEH mutant, characterized in that: The limonene epoxide hydrolase LEH mutant is any one of the following (1)-(9): (1) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to leucine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged; (2) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to isoleucine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged; (3) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to valine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged; (4) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to isoleucine, and mutating the 55th amino acid from asparagine to alanine, while keeping the other amino acid sequences unchanged; (5) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, and mutating the 55th amino acid from asparagine to proline, while keeping the other amino acid sequences unchanged; (6) A protein obtained by mutating the 53rd amino acid of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, and mutating the 55th amino acid from asparagine to alanine, while keeping the other amino acid sequences unchanged; (7) A protein obtained by mutating the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, the amino acid at position 55 from asparagine to alanine, the isoleucine at position 80 to phenylalanine, the leucine at position 114 to valine, and the isoleucine at position 116 to valine, while keeping the other amino acid sequences unchanged; (8) A protein obtained by mutating the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, the amino acid at position 55 from asparagine to alanine, and the isoleucine at position 116 to valine, while keeping the other amino acid sequences unchanged; (9) A protein obtained by mutating the amino acid at position 53 of the limonene epoxide hydrolase LEH sequence from tyrosine to phenylalanine, the amino acid at position 55 from asparagine to alanine, the isoleucine at position 80 to phenylalanine, and the isoleucine at position 116 to valine, while keeping the other amino acid sequences unchanged; The amino acid sequence of the limonene epoxide hydrolase LEH in the above protein is shown in SEQ ID No.
2.
2. The fusion protein of the limonene epoxide hydrolase LEH mutant according to claim 1, characterized in that: A fusion protein obtained by connecting a tag to its N-terminus or / and C-terminus.
3. The fusion protein of the limonene epoxide hydrolase LEH mutant according to claim 2, characterized in that: The tag is Poly-Arg, Poly-His, FLAG, Strep-tag II or c-myc.
4. The fusion protein of the limonene epoxide hydrolase LEH mutant according to claim 3, characterized in that: The tag is RRRRR, HHHHHH, DYKDDDDK, WSHPQFEK, or EQKLISEEDL.
5. A nucleic acid molecule encoding the limonene epoxide hydrolase LEH mutant according to claim 1, or a fusion protein of the limonene epoxide hydrolase LEH mutant according to any one of claims 2 to 4.
6. The nucleic acid molecule according to claim 5, characterized in that The nucleic acid molecule is DNA or RNA.
7. An expression cassette, a recombinant vector, or a recombinant microorganism containing the limonene epoxide hydrolase LEH mutant according to claim 1, or a fusion protein of the limonene epoxide hydrolase LEH mutant according to any one of claims 2 to 4; The expression cassette includes a promoter for initiating transcription of a gene encoding a limonene epoxide hydrolase LEH mutant, and a terminator for terminating transcription of a gene encoding a limonene epoxide hydrolase LEH mutant; The recombinant vector is a bacterial plasmid, a bacteriophage, a yeast plasmid or a retrovirus packaging plasmid; The recombinant microorganism is yeast, bacteria, algae or fungi; The recombinant cell line is a plant cell or an animal cell and does not include propagation materials.
8. Use of the limonene epoxide hydrolase LEH mutant according to claim 1, or its encoding gene in the following aspects: A1) Catalyzes the production of 4-(2-oxirane-1-yl)-butanol (S) -(tetrahydro-2H-pyran-2-yl)methanol; A2) Preparation of chiral (tetrahydro-2H-pyran-2-yl)methanol; A3) Catalytic synthesis of 2-(3-phenyloxetane-3-yl)ethanol (S) -(3-phenyltetrahydrofuran-3-yl)methanol; A4) Synthesis or preparation of chiral (3-substituted tetrahydrofuran-3-yl)methanol; A5) Catalytic synthesis of N-benzyl-2-(3-phenyloxetane-3-yl)ethylamine (S) -(1-benzyl-3-phenyltetrahydropyridin-3-yl)methanol; A6) Synthesis or preparation of (1-benzyl-3-aryltetrahydropyridin-3-yl)methanol; A7) Catalyzes the synthesis of (1-benzyl-3-phenylpiperidin-3-yl)methanol from N-benzyl-2-(3-phenyloxetane-3-yl)propylamine; A8) Synthesis or preparation of (1-benzyl-3-substituted piperidin-3-yl)methanol; A9) catalyzes the production of 4-(3-methyloxirane-2-yl)-1-butanol ( S )-1-(tetrahydro-2H-pyran-2-yl)ethan-1-ol; A10) catalyzes the production of 4-(3,3-dimethyloxirane-2-yl)-1-butanol ( S )-2-(tetrahydro-2H-pyran-2-yl)propan-2-ol.
9. The use according to claim 8, characterized in that The (3-substituted tetrahydrofuran-3-yl)methanol is any one of the following: (3-(4-methylphenyl)tetrahydrofuran-3-yl)methanol, (3-(3-methylphenyl)tetrahydrofuran-3-yl)methanol, (3-(3,5-dimethylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-ethylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-methoxyphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-methylthiophenyl)tetrahydrofuran-3-yl)methanol, (3-( (3-(4-naphthylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-fluorophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-chlorophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-bromophenyl)tetrahydrofuran-3-yl)methanol, (3-(4-trifluoromethylphenyl)tetrahydrofuran-3-yl)methanol, (3-(4-benzyl)tetrahydrofuran-3-yl)methanol, (3-(4-ethyl)tetrahydrofuran-3-yl)methanol, (3-phenyltetrahydro-2H-pyran-3-yl)methanol; The (1-benzyl-3-aryltetrahydropyridine-3-yl)methanol is any one of the following: (1-benzyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-allyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-propargyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-n-butyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-phenyl-3-phenyltetrahydropyridine-3-yl)methanol, (1-phenyl-3-p-tolyltetrahydropyridine-3-yl)methanol, (1-phenyl-3-p-chlorophenyltetrahydropyridine-3-yl)methanol, (1-benzyl-3-(p-tolyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-3-(m-tolyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(3,5-xylyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-ethylphenyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-methoxyphenyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-methylthiophenyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(4-naphthyl)tetrahydropyridin-3-yl)methanol, (1-benzyl-(p-fluorophenyl)tetrahydropyridin-3-yl)methanol; The (1-benzyl-3-substituted piperidin-3-yl)methanol may be any one of the following: (1-benzyl-3-phenylpiperidin-3-yl)methanol, (1-benzyl-3-benzylpiperidin-3-yl)methanol.
10. The use according to claim 8, characterized in that In the application, the whole-cell catalysis is achieved by recombinant host cells, wherein the host cells can be prokaryotic cells or lower eukaryotic cells.
11. The use according to claim 10, characterized in that The prokaryotic cell is a bacterium; the lower eukaryotic cell is a yeast cell.
12. The use according to claim 11, characterized in that The prokaryotic cell is Escherichia coli.
13. The use according to claim 12, characterized in that The prokaryotic cell is E. coli BL21(DE3).
14. The use according to claim 13, characterized in that Said E. coli The induction culture of BL21 (DE3) is to add IPTG to the culture system to a final concentration of 0.05-1.0 mmol / L, and induce the culture at 20-30 °C for 10-20 hours.
15. The use according to claim 8, characterized in that The reaction of using the limonene epoxide hydrolase LEH mutant as a biological enzyme to catalyze the substrate to generate (S)-(tetrahydro-2H-pyran-2-yl)methanol or (S)-(3-phenyltetrahydrofuran-3-yl)methanol is carried out in a phosphate buffer with a concentration of 0.001-0.1 mol / L and a pH of 6-8.
16. The use according to claim 15, characterized in that The concentration of the substrate in the reaction system is 1-50 mmol / L; the concentration of the crude enzyme powder of the limonene epoxide hydrolase LEH mutant in the reaction system is 1-10 g / L.
17. The use according to claim 12, characterized in that The concentration of the whole cells of the limonene epoxide hydrolase LEH mutant in the application is 50-500 g / L; the concentration of the limonene epoxide hydrolase lysate in the reaction system is 50-500 g / L, and the volume percentage of acetonitrile in the reaction system is 5-20%.
18. The use according to claim 17, characterized in that The reaction adopts an asymmetric reduction reaction system, which is composed of: 5 mmol / L of substrate 4-(oxiran-2-yl)-1-butanol or 2-(3-phenyloxetane-3-yl)ethanol, 3-15% by volume acetonitrile as a cosolvent, whole cells expressing a limonene epoxide hydrolase mutant, lysozyme, DNase I, and the balance is potassium phosphate buffer.
Citation Information
Patent Citations
Stereoselectivity-improved phaseolus-vulgaris epoxy hydrolytic enzyme mutant
CN108559737A
Leucine-5-hydroxylase mutant and application thereof
CN109576234A
